George Mulligan

George Mulligan is a seasoned expert in translational medicine and oncology with extensive experience in leading scientific teams and developing biomarker strategies. Currently serving as Chief Scientific Officer at the Multiple Myeloma Research Foundation since March 2022, George has held previous positions including Chief Development Officer at Bantam Pharmaceutical and Chief Scientific Officer at Mitobridge, Inc. Between 2007 and 2015, George contributed to Takeda as Senior Director of Translational Medicine, where responsibilities included overseeing biomarker clinical strategies for key oncology drugs. With a strong educational background, including a PhD in Cellular and Developmental Biology from the State University of New York at Stony Brook and post-doctoral studies at MIT Center for Cancer Research, George possesses a robust foundation in cancer research and development.